Dergunov Alexander D, Litvinov Dmitry Y, Malkov Artem A, Baserova Veronika B, Nosova Elena V, Dergunova Liudmila V
Laboratory of Structural Fundamentals of Lipoprotein Metabolism, National Research Centre for Preventive Medicine, Moscow, Russia.
Laboratory of Structural Fundamentals of Lipoprotein Metabolism, National Research Centre for Preventive Medicine, Moscow, Russia.
Biochim Biophys Acta Mol Cell Biol Lipids. 2021 Jan;1866(1):158814. doi: 10.1016/j.bbalip.2020.158814. Epub 2020 Sep 19.
We studied the mechanism of HDL denaturation with concomitant apoA-I dissociation with HDL preparations from 48 patients with a wide range of plasma HDL-C and evaluated the contribution of lipid-free apoA-I into cholesterol efflux from macrophage, in particular, mediated by cholesterol transporter ABCA1. We prepared HDL by precipitation of apoB-containing lipoproteins by polyethylene glycol and used the chaotropic agent urea to denature HDL preparations. Apo-I dissociation from urea-treated HDL was assessed by the increase of preβ-band fraction with agarose gel electrophoresis followed by electro transfer and immunodetection and by the increase of ABCA1-mediated efflux of fluorescent analogue BODIPY-Cholesterol from RAW 264.7 macrophages. The HDL denaturation is governed by a single transition to fully dissociated apoA-I and the transition cooperativity decreases with increasing HDL-C. The apoA-I release depends on phospholipid concentration of HDL preparation and HDL compositional and structural heterogeneity and is well described by apolipoprotein partition between aqueous and lipid phases. Dissociated apoA-I determines the increase of ABCA1-mediated efflux of BODIPY-Cholesterol from RAW 264.7 macrophages to patient HDL. The increase in apoA-I dissociation is associated with the increase of ABCA1 gene transcript in peripheral blood mononuclear cells from patients. The low level of plasma HDL particles may be compensated by their increased potency for apoA-I release, thus suggesting apoA-I dissociation as a new HDL functional property.
我们研究了高密度脂蛋白(HDL)变性机制以及伴随载脂蛋白A-I(apoA-I)与48例血浆HDL-C水平范围广泛的患者的HDL制剂解离的情况,并评估了无脂apoA-I对巨噬细胞胆固醇流出的贡献,特别是由胆固醇转运蛋白ABCA1介导的胆固醇流出。我们通过用聚乙二醇沉淀含apoB的脂蛋白来制备HDL,并使用离液剂尿素使HDL制剂变性。通过琼脂糖凝胶电泳增加前β带分数,随后进行电转移和免疫检测,以及通过增加RAW 264.7巨噬细胞中ABCA1介导的荧光类似物BODIPY-胆固醇流出,来评估apo-I从经尿素处理的HDL中的解离情况。HDL变性由向完全解离的apoA-I的单一转变控制,并且转变协同性随着HDL-C的增加而降低。apoA-I的释放取决于HDL制剂的磷脂浓度以及HDL的组成和结构异质性,并且可以通过载脂蛋白在水相和脂质相之间的分配很好地描述。解离的apoA-I决定了RAW 264.7巨噬细胞中ABCA1介导的BODIPY-胆固醇向患者HDL流出的增加。apoA-I解离的增加与患者外周血单核细胞中ABCA1基因转录本的增加相关。血浆HDL颗粒水平低可能通过其apoA-I释放能力的增加得到补偿,因此表明apoA-I解离是HDL的一种新功能特性。